相关实验视频
Updated: Sep 12, 2025

09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
7.6K
微RNA-27b通过准Mff/MAVS轴来缓解败血性心肌病
Xincai Wang1, Long Huang1, Jingqing Xu1
1Department of Critical Care Medicine, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fujian Provincial Center for Critical Care Medicine, Fujian Provincial Key Laboratory of Critical Care Medicine, Fuzhou, China.
Frontiers in cellular and infection microbiology
|August 6, 2025
概括
微RNA-27b (miR-27b) 通过向Mff/MAVS通路来保护抗败血性心肌病 (SCM). 这一发现突出了miR-27b作为SCM的潜在治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 线粒体生物学 线粒体生物学
背景情况:
- 败血性心肌病 (SCM) 是败血症的严重并发症,其特征是心脏功能障碍和心肌损伤.
- 线粒体功能障碍在SCM的发病过程中起着至关重要的作用.
- 在SCM中调节线粒体动态和炎症的microRNAs的作用仍然不完全理解.
研究的目的:
- 研究微RNA-27b (miR-27b) 在败血性心肌病 (SCM) 中的保护作用.
- 阐明miR-27b在SCM中的线粒体裂变因子 (Mff) /线粒体抗病毒信号蛋白 (MAVS) 轴上的调节机制.
主要方法:
- 来自败血症患者心脏组织的转录组数据的分析 (GSE79962).
- 在SCM患者,败血症患者和健康对照中测量血清miR-27b水平.
- 建立由脂聚糖 (LPS) 诱导的小鼠SCM和HL-1心肌细胞模型.
- 使用miR-27b调节器和Mff干预的分子机制的研究,加上RT-qPCR,西部斑点,免疫光和电子显微镜.
主要成果:
- 在SCM心脏组织和血清中观察到miR-27b的下调.
- 由LPS诱导的SCM模型表现出心脏功能障碍,心肌损伤和线粒体异常.
- miR-27b针对Mff,维持线粒体平衡,减轻LPS诱导的炎症和亡;Mff过度表达逆转了这些影响.
结论:
- miR-27b通过准Mff/MAVS轴来缓解SCM中的心肌损伤和炎症.
- 通过miR-27b维持线粒体平衡,为SCM提供了一个潜在的治疗策略.
- miR-27b代表了SCM的一个有前途的新疗法标.
相关概念视频
Cardiomyopathy IV: Restrictive Cardiomyopathy
31
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
31
Cardiomyopathy III: Hypertrophic Cardiomyopathy
48
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
48
Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
MicroRNAs
21.7K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.7K
Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34

